clinical trial · NCT04721106
Korea Post Marketing Surveillance (PMS) Study of Vizimpro
Pfizer·—·completed·n = 188
Lung NeoplasmsVizimpro
brief summary
Vizimpro will be approved for the treatment of EGFR NSLCL 1L in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS. Post marketing surveillance is required to determine any problems or questions associated with Vizimpro after marketing in Korea, with regard to the following clauses under conditions of general clinical practice. Therefore, through this study, effectiveness and safety of Vizimpro will be observed.
started
Mar 7, 2021
primary completion
Jan 19, 2026
completion
Jan 19, 2026
last updated
Feb 10, 2026
official title
A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Vizimpro®
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol